The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Novartis had already gained rights to all cancer indications for Arzerra (ofatumumab) as part of its acquisition of GSK's oncology products in an asset-swap deal which closed earlier this year ...

GSK plc GSK reported fourth-quarter 2024 core ... The upside can be attributed to rising sales of its HIV and oncology ...

GSK’s return to oncology is part of a strategic shift as ... and our priority is to make sure we get our products to the people that need them.” (Updates with shares in fifth paragraph) ...

1). The insights they have provided through their partnership in pan-oncology and disease-specific patient councils are reflected in the design of clinical trials and in building GSK’s pipeline ...